E-MTAB-977 - Treatment of dendritic cells and monocytes from immunotherapy treated patients with ONTAK
Released on 4 September 2013, last updated on 2 May 2014
In this experiment, dendritic cells and monocytes obtained from melanoma patients who underwent immunotherapy were stimulated with a maturation cocktail then either treated or not treated with denlieukin diftitox (DD; ONTAK) and then subjected to transcription profiling to investigate the effects of DD on the maturation and activation of dendritic cells and monocytes.
transcription profiling by array, compound treatment design
Denileukin diftitox (ONTAK TM) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg. Andreas S. Baur, Manfred B. Lutz, Stephan Schierer, Luca Beltrame, Gabi Theiner, Elisabeth Zinser, Christian Ostalecki, Gordon Heidkamp, Ina Haendle, Michael Erdmann, Manuel Wiesinger, Waltraud Leisgang, Stefanie Gross, Ansgar J. Pommer, Eckhart Kämpgen, Diana Dudziak, Alexander Steinkasserer, Duccio Cavalieri, Beatrice Schuler-Thurner, and Gerold Schuler. Blood (2013)